Drug Regimen Review

The DRR looks at the whole regimen, prescriptions plus OTCs and supplements, for potentially clinically significant issues:

• Drug-drug and drug-disease interactions
• Duplicate therapy, including same-class drugs from different prescribers
• Omissions, meaning indicated medications the patient is not receiving
• Ineffective drug therapy and significant side effects or adverse reactions
• Dosage errors and impractical schedules
• Nonadherence, whether intentional or from confusion, cost, or access

It builds on medication reconciliation: first establish what the patient actually takes, then screen that reality for problems.

Three items document the DRR. M2001 asks whether the review identified potential clinically significant medication issues at start or resumption of care. M2003 asks whether the agency contacted the physician or allowed practitioner and completed prescribed or recommended actions by midnight of the next calendar day after identifying the issue. M2005, collected at transfer and discharge, asks the same follow-up question across the whole episode. The midnight-of-next-day standard is the operational teeth: identifying a significant issue starts a clock that requires same-day or next-day practitioner contact and completed follow-through, not a note in the chart.

The DRR items support a Home Health Quality Reporting Program process measure on whether reviews were conducted and identified issues received timely follow-up, so performance is visible beyond the chart. Surveyors also treat medication review as core Conditions of Participation content within the comprehensive assessment. The compliance failure patterns are consistent: reviews documented as no issues found on regimens that plainly have them, issues identified without documented practitioner contact, and follow-up that happened but missed the midnight deadline or was never documented as completed.

Agencies get in trouble when M2001 becomes a reflexive checkbox. What works: train clinicians on high-risk drug classes common in home health, anticoagulants, insulin and other hypoglycemics, opioids, diuretics, and anticholinergics; give them a practical screening workflow or clinical decision support rather than memory alone; make practitioner contact easy to execute and document the same day; and have QA sample DRR answers against medication profiles to catch reviews that could not plausibly be clean. A DRR that regularly finds and resolves real issues is also one of the strongest levers on rehospitalization.